Catherine A. Sohn
CIK 1555132 · last filed 2026-05-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.82M
Companies
7
Total Filings
64
Lifetime Open-Market Net
-$4.57M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALT | Director | 1,500 | $2.99 | $4.5K | $7.9K | 8 | 2026-05-01 |
| MAZE | Director | 0 | $27.88 | $0 | -$1.15M | 2 | 2026-01-08 |
| JAZZ | Director | 14,868 | $256.92 | $3.82M | -$3.50M | 17 | 2023-08-15 |
| LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Director | 54,069 | $8.76 | $473.6K | $11.2K | 20 | 2022-06-07 |
| Axcella Health Inc. (AXLA) Delisted | Director | 40 | $0.40 | $16 | $4.9K | 5 | 2022-05-23 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | 2,500 | $0.08 | $208 | $57.5K | 6 | 2022-05-13 |
| PALISADE BIO, INC. (CUR) Delisted | Director | 106,952 | — | — | $0 | 2 | 2015-07-06 |
Recent Filings · Page 2 of 7
64 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-02 | JAZZ | Notice (144) | −3,075 | -$341.3K | EDGAR |
| 2023-09-29 | ALT | Grant (A) | — | $0 | EDGAR |
| 2023-08-15 | JAZZ | Mixed | +1,834 | -$171.5K | EDGAR |
| 2023-08-14 | JAZZ | Notice (144) | −2,561 | -$346.2K | EDGAR |
| 2023-03-27 | ALT | Grant (A) | — | $0 | EDGAR |
| 2022-08-09 | JAZZ | Mixed | +1,472 | -$165.9K | EDGAR |
| 2022-06-07 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Mixed | +7,059 | $67.1K | EDGAR |
| 2022-06-02 | LIFECORE BIOMEDICAL, INC. \DE\ (LNDC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-23 | Axcella Health Inc. (AXLA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-13 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.